What Alverine Citrate Treats: Main Uses and Benefits

Alverine Citrate is a medication applied across domains where additional symptomatic support is needed for conditions characterized by periods of heightened symptoms. Its use is relevant in contexts marked by increased discomfort or tension, commonly used across conditions presenting with acute episodes in the gastrointestinal tract and pelvic area.

Alverine citrate is used for easing symptoms of smooth muscle spasm in conditions such as Irritable Bowel Syndrome (IBS), painful diverticular disease of the colon, and primary dysmenorrhoea (menstrual cramps).

The medicine generally assists with easing symptom clusters related to physical discomfort, such as cramping abdominal pain, which may interfere with daily functioning. This is often used during phases when symptoms become more noticeable.

Quick Fact: Supports Management of Spasms and Cramps

It supports general well-being during symptomatic phases by contributing to improved comfort during periods of heightened symptoms and assists with maintaining functional stability. The medication's role is summarized as helping provide symptomatic support, which may assist patients in coping more steadily.

“Supports the patient during difficult episodes by easing distress.”

Regulatory References

1. HPRA Summary of Product Characteristics

Official Eligibility Profile

Regulatory documents define specific populations who are eligible, restricted, or absolutely prohibited from using Alverine Citrate.

Eligibility Status	Applicable Population(s)
Contraindicated	Patients with hypersensitivity to the medicine or any excipient.
	Patients with intestinal obstruction or paralytic ileus.
Use Not Recommended	Pregnant individuals and breastfeeding mothers.
	Children below the age of 12 years.

---

Eligibility Summary

Alverine Citrate use is established for adults, including older adults, with regulatory documentation stating the dose applies to this general group. Use is absolutely prohibited (contraindicated) for individuals diagnosed with an intestinal obstruction or paralytic ileus, as well as anyone with a known allergy to the components. Furthermore, the medicine is officially not recommended for children under 12 or during pregnancy and lactation, based on limited safety data in these populations documented by health authorities. No formal contraindication is established regarding hepatic or renal impairment in the regulatory labeling.

The regulatory documentation for Alverine Citrate consistently details the drug’s interaction profile with other medicinal products and substances. According to the official prescribing information published by national government health authorities, no formal interactions are cited in the dedicated regulatory sections. This status is the official basis for interaction-related information provided to patients and healthcare professionals.

This specific regulatory position establishes that no specific drug combinations are classified as formally contraindicated based on an interaction effect with Alverine Citrate. The labeling does not specify any co-administered medicines that require mandatory timing separation rules or altered administration. The absence of documented interactions extends across major regulatory classifications.

For instance, the regulatory text does not cite any substances that formally modify the exposure of Alverine Citrate through pharmacokinetic mechanisms, such as metabolic enzyme (CYP) or transporter-mediated effects. Similarly, the documentation does not contain information regarding pharmacodynamic interactions or specific restrictions concerning the co-administration of Alverine Citrate with food, alcohol, or herbal products based on documented interaction risks. The drug’s interaction structure is officially defined by this lack of citation across all standardized regulatory categories.

Alverine Citrate exerts its effect primarily by modulating smooth muscle function within the gastrointestinal tract and uterus. Its mechanism involves a multifaceted interaction with intracellular and receptor pathways.

Molecular and Intracellular Pathways:

1. L-type Calcium Channel Modulation: Alverine inhibits the inactivation of L-type voltage-gated calcium channels on the smooth muscle cell membrane. This action can increase spontaneous calcium influx and action potential frequency.
2. Contractile Protein Sensitization: The compound decreases the sensitivity of the smooth muscle contractile apparatus to intracellular calcium (Ca^2+), potentially via the Rho kinase (ROCK) pathway inhibition. This calcium-independent mechanism suppresses muscle contraction evoked by external stimuli.
3. Serotonin Receptor Antagonism: Alverine functions as an antagonist at the 5-HT1A receptor subtype. This interaction modulates neuronal excitability and signaling within the enteric nervous system.

System-Level Physiological Consequences:

By concurrently reducing the calcium sensitivity of contractile proteins and acting as a 5-HT1A receptor antagonist, Alverine decreases the overall contractile force of stimulated smooth muscle. This dual action results in direct relaxation and reduced excitability of the alimentary tract and uterine smooth muscle tissues.

How to Use Alverine Citrate

Alverine Citrate is an antispasmodic medication administered orally, with specific dosing and handling instructions to ensure proper use. The medicine is supplied as hard capsules, typically in 60 mg and 120 mg strengths.

Official Administration Guidelines

The following instructions detail the standardized procedures for taking Alverine Citrate:

Property	Official Instruction
Route of Administration	Oral use
Standard Single Dose (Adults)	60 mg to 120 mg per administration
Dosing Frequency	One to three times daily
With or Without Food	May be taken with or without food
Handling Precaution	Capsules must be swallowed whole; do not chew

Population-Specific Use

Standard guidelines outline specific high-level rules regarding use in certain groups:

• Older Adults (The Elderly): The dosage and administration schedule are the same as those for adults.
• Children: The use of Alverine Citrate is not recommended for children below the age of 12 years.

Duration of Use

Patients are advised to seek medical guidance if their symptoms worsen or do not show improvement after 2 weeks of treatment. If a dose is missed, individuals should resume the standard schedule and not take a double dose to compensate.

Research Evidence / Overview of Studies for Alverine Citrate

Evidence for Use in Irritable Bowable Syndrome (IBS)

Research exploring Alverine Citrate for conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome, is primarily composed of short-term, randomized controlled trials (RCTs). These studies were applied in research examining patient-reported experiences, where researchers monitored outcomes related to physical discomfort, such as abdominal pain, cramping, and bloating, typically over periods of 4 to 12 weeks.

Studies have explored both the single-ingredient formulation of Alverine Citrate and a combination formulation. Findings describe patterns observed in these studies related to changes in abdominal symptoms. However, findings were inconsistent across some studies comparing the single agent to a control substance, which can complicate the interpretation of symptomatic change. Research highlights that the trials focusing on the combination formulation reported differences in measured outcomes compared to control.

Evidence for Use in Painful Diverticular Disease

Alverine Citrate was studied for conditions involving periods of heightened symptoms such as painful diverticular disease. Its inclusion in official regulatory summaries for this indication is based on its pharmacological classification as an antispasmodic agent. Research explored the agent’s use, observing patient-reported outcomes related to painful smooth muscle spasm and cramping. Evidence in this area is limited and heterogeneous, primarily serving to contribute to the broader evidence landscape for antispasmodics.

Research on Primary Dysmenorrhoea (Menstrual Cramps)

Research has explored the use of Alverine Citrate for conditions presenting with cycles of stability and flare-ups, based on its pharmacological classification as an antispasmodic agent. Studies conducted during periods of increased symptom activity evaluated outcomes describing episodic or acute changes in pain intensity using patient-reported scales. These studies were typically smaller and observed responses over defined time intervals, often tracking changes across two to three menstrual cycles. Sample sizes were modest, and more extensive, rigorous controlled research is needed to provide a fuller understanding of observed symptom patterns in this area.

What is Still Uncertain About Alverine Citrate Research

The evidence highlights what is known—and what is still uncertain—emphasizing that research does not determine whether an individual will respond similarly, and that certainty remains low regarding long-term outcomes. Follow-up durations were limited across the main efficacy trials, and comparative evidence is lacking in some indications. Findings were inconsistent in some placebo-controlled trials for the single-ingredient formulation for IBS.

Key Studies & References

1. Summary of Product Characteristics for Alverine Citrate (HPRA, Ireland)
2. WHO Collaborating Centre for Drug Statistics Methodology: ATC Code A03AA05 (Alverine)

Common questions about Alverine Citrate (FAQ)

Q: Can I stop taking Alverine Citrate once my symptoms are gone?

The official product information advises against stopping treatment suddenly unless directed by a healthcare professional. This medication is often used as needed or for defined periods. It is important to continue treatment exactly as prescribed, and to discuss any changes in feeling or a desire to stop with a healthcare professional before making any changes.

---

Q: Does Alverine Citrate guarantee that my symptoms will be eliminated?

No medication can guarantee the elimination of all symptoms. Alverine Citrate is indicated for the relief of certain spasms and pain in specific patient populations. Adherence to the prescribed regimen is considered a key factor in achieving potential therapeutic benefits. Discuss your individual treatment plan with your healthcare provider.

---

Q: When is the best time of day to take Alverine Citrate?

The usual recommended dosing schedule and timing should be followed as directed by the prescribing physician. The specific time of day and frequency are details best discussed with your doctor to align with your personal lifestyle and medical needs. Taking the medication consistently as instructed helps maintain stable therapeutic levels in the body, if prescribed regularly. Alverine Citrate may be taken with or without food, as indicated in the product labeling.

How to Store and Dispose of Alverine Citrate?

The storage and disposal of Alverine Citrate must align strictly with official regulatory guidelines to preserve its stability and ensure environmental safety.

Storage Requirements

• Temperature and Protection: The medicine must be stored at a temperature not exceeding 25°C (or 30°C for some presentations). It must be kept in its original package to ensure protection from light and moisture.
• Child Safety: Alverine Citrate must be stored out of the sight and reach of children.
• Stability: Do not use the medicine after the expiry date (EXP) indicated on the packaging.

Disposal Instructions

• Waste Protocol: The unused or expired product must not be disposed of via wastewater or household waste.
• Official Disposal: Unused material must be returned to a pharmacy or disposed of in accordance with local pharmaceutical waste requirements.